400 related articles for article (PubMed ID: 24916698)
1. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.
Iglesia MD; Vincent BG; Parker JS; Hoadley KA; Carey LA; Perou CM; Serody JS
Clin Cancer Res; 2014 Jul; 20(14):3818-29. PubMed ID: 24916698
[TBL] [Abstract][Full Text] [Related]
2. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.
Schwede M; Spentzos D; Bentink S; Hofmann O; Haibe-Kains B; Harrington D; Quackenbush J; Culhane AC
PLoS One; 2013; 8(3):e57799. PubMed ID: 23536770
[TBL] [Abstract][Full Text] [Related]
3. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
4. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
[TBL] [Abstract][Full Text] [Related]
6. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
[TBL] [Abstract][Full Text] [Related]
7. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study.
Zhang L; Liu Z; Zhu J
Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671
[TBL] [Abstract][Full Text] [Related]
8. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers.
Krutilina R; Sun W; Sethuraman A; Brown M; Seagroves TN; Pfeffer LM; Ignatova T; Fan M
Breast Cancer Res; 2014 Jul; 16(4):R78. PubMed ID: 25069832
[TBL] [Abstract][Full Text] [Related]
10. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
11. A bioinformatics analysis of the clinicopathological and prognostic significance of
Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
[TBL] [Abstract][Full Text] [Related]
12. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.
Bhardwaj A; Ganesan N; Tachibana K; Rajapakshe K; Albarracin CT; Gunaratne PH; Coarfa C; Bedrosian I
PLoS One; 2015; 10(5):e0127678. PubMed ID: 26000884
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.
Miller LD; Chou JA; Black MA; Print C; Chifman J; Alistar A; Putti T; Zhou X; Bedognetti D; Hendrickx W; Pullikuth A; Rennhack J; Andrechek ER; Demaria S; Wang E; Marincola FM
Cancer Immunol Res; 2016 Jul; 4(7):600-10. PubMed ID: 27197066
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.
Tell RW; Horvath CM
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12787-92. PubMed ID: 25139989
[TBL] [Abstract][Full Text] [Related]
15. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
[TBL] [Abstract][Full Text] [Related]
16. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
17. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer.
Ray M; Ruffalo MM; Bar-Joseph Z
Genes Chromosomes Cancer; 2019 Jan; 58(1):34-42. PubMed ID: 30285311
[TBL] [Abstract][Full Text] [Related]
18. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
Hanker LC; Rody A; Holtrich U; Pusztai L; Ruckhaeberle E; Liedtke C; Ahr A; Heinrich TM; Sänger N; Becker S; Karn T
Breast Cancer Res Treat; 2013 Jan; 137(2):407-16. PubMed ID: 23242614
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
[TBL] [Abstract][Full Text] [Related]
20. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.
Vollan HK; Rueda OM; Chin SF; Curtis C; Turashvili G; Shah S; Lingjærde OC; Yuan Y; Ng CK; Dunning MJ; Dicks E; Provenzano E; Sammut S; McKinney S; Ellis IO; Pinder S; Purushotham A; Murphy LC; Kristensen VN; ; Brenton JD; Pharoah PD; Børresen-Dale AL; Aparicio S; Caldas C
Mol Oncol; 2015 Jan; 9(1):115-27. PubMed ID: 25169931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
